Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome

Endocrinol Diabetes Nutr (Engl Ed). 2024 Jan;71(1):19-30. doi: 10.1016/j.endien.2024.01.003. Epub 2024 Feb 7.

Abstract

Irritable bowel syndrome (IBS) is a gastrointestinal functional disorder mainly characterised by abdominal pain, bloating and altered bowel habits. Dysbiosis might seem to be involved in the pathogenesis of the disease. Probiotics represent a potential treatment, since these could favour the functional microbiota and improve symptoms. The aim was to review the effectiveness of the use of probiotics in IBS symptomatology, analysing the influence of duration and dose. 18 articles were included. At the individual level, Lactobacillus, Bifidobacterium and Bacillus could be useful in the treatment of symptoms. Bifidobacterium bifidum reported the best results (1 × 109 CFU/day for 4 weeks). The most effective combination was 2 Lactobacillus strains, one of Bifidobacterium and one of Streptococcus (4 × 109 CFU/day for 4 weeks). Future clinical trials should confirm these results and analyse the difference between individual and combined treatments.

Keywords: Irritable bowel syndrome; Microbiota; Probiotics; Probióticos; Síndrome del intestino irritable.

Publication types

  • Review

MeSH terms

  • Abdominal Pain / etiology
  • Abdominal Pain / therapy
  • Bifidobacterium
  • Humans
  • Irritable Bowel Syndrome* / therapy
  • Lactobacillus
  • Probiotics* / therapeutic use